Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99


Cadmium inhibits ABCG2 transporter function in BeWo choriocarcinoma cells and MCF-7 cells overexpressing ABCG2.

Kummu M, Sieppi E, Wallin K, Rautio A, Vähäkangas K, Myllynen P.

Placenta. 2012 Oct;33(10):859-65. doi: 10.1016/j.placenta.2012.07.017. Epub 2012 Aug 11. Erratum in: Placenta. 2012 Dec;33(12):1059.


Expression and functional activity of breast cancer resistance protein (BCRP, ABCG2) transporter in the human choriocarcinoma cell line BeWo.

Ceckova M, Libra A, Pavek P, Nachtigal P, Brabec M, Fuchs R, Staud F.

Clin Exp Pharmacol Physiol. 2006 Jan-Feb;33(1-2):58-65.


ABCG2/BCRP decreases the transfer of a food-born chemical carcinogen, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in perfused term human placenta.

Myllynen P, Kummu M, Kangas T, Ilves M, Immonen E, Rysä J, Pirilä R, Lastumäki A, Vähäkangas KH.

Toxicol Appl Pharmacol. 2008 Oct 15;232(2):210-7. doi: 10.1016/j.taap.2008.07.006. Epub 2008 Jul 18.


Expression and function of ABCB1 and ABCG2 in human placental tissue.

Kolwankar D, Glover DD, Ware JA, Tracy TS.

Drug Metab Dispos. 2005 Apr;33(4):524-9. Epub 2005 Jan 7.


Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells.

Robey RW, Medina-Pérez WY, Nishiyama K, Lahusen T, Miyake K, Litman T, Senderowicz AM, Ross DD, Bates SE.

Clin Cancer Res. 2001 Jan;7(1):145-52.


Linsitinib (OSI-906) antagonizes ATP-binding cassette subfamily G member 2 and subfamily C member 10-mediated drug resistance.

Zhang H, Kathawala RJ, Wang YJ, Zhang YK, Patel A, Shukla S, Robey RW, Talele TT, Ashby CR Jr, Ambudkar SV, Bates SE, Fu LW, Chen ZS.

Int J Biochem Cell Biol. 2014 Jun;51:111-9. doi: 10.1016/j.biocel.2014.03.026. Epub 2014 Apr 12.


Expression of the ATP-binding cassette membrane transporter, ABCG2, in human and rodent brain microvessel endothelial and glial cell culture systems.

Lee G, Babakhanian K, Ramaswamy M, Prat A, Wosik K, Bendayan R.

Pharm Res. 2007 Jul;24(7):1262-74. Epub 2007 Mar 23.


Hop-derived prenylflavonoids are substrates and inhibitors of the efflux transporter breast cancer resistance protein (BCRP/ABCG2).

Tan KW, Cooney J, Jensen D, Li Y, Paxton JW, Birch NP, Scheepens A.

Mol Nutr Food Res. 2014 Nov;58(11):2099-110. doi: 10.1002/mnfr.201400288. Epub 2014 Aug 6.


The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2.

Sen R, Natarajan K, Bhullar J, Shukla S, Fang HB, Cai L, Chen ZS, Ambudkar SV, Baer MR.

Mol Cancer Ther. 2012 Sep;11(9):2033-44. doi: 10.1158/1535-7163.MCT-12-0302. Epub 2012 Jul 9.


Epidermal growth factor-mediated activation of the map kinase cascade results in altered expression and function of ABCG2 (BCRP).

Meyer zu Schwabedissen HE, Grube M, Dreisbach A, Jedlitschky G, Meissner K, Linnemann K, Fusch C, Ritter CA, Völker U, Kroemer HK.

Drug Metab Dispos. 2006 Apr;34(4):524-33. Epub 2006 Jan 13.


A novel two mode-acting inhibitor of ABCG2-mediated multidrug transport and resistance in cancer chemotherapy.

Peng H, Dong Z, Qi J, Yang Y, Liu Y, Li Z, Xu J, Zhang JT.

PLoS One. 2009 May 24;4(5):e5676. doi: 10.1371/journal.pone.0005676.


Overlapping substrate and inhibitor specificity of human and murine ABCG2.

Bakhsheshian J, Hall MD, Robey RW, Herrmann MA, Chen JQ, Bates SE, Gottesman MM.

Drug Metab Dispos. 2013 Oct;41(10):1805-12. doi: 10.1124/dmd.113.053140. Epub 2013 Jul 18.


Toxicokinetics of the food-toxin IQ in human placental perfusion is not affected by ABCG2 or xenobiotic metabolism.

Immonen E, Kummu M, Petsalo A, Pihlaja T, Mathiesen L, Nielsen JK, Knudsen LE, Vähäkangas K, Myllynen P.

Placenta. 2010 Jul;31(7):641-8. doi: 10.1016/j.placenta.2010.05.002. Epub 2010 Jun 8.


The multidrug transporter ABCG2 (BCRP) is inhibited by plant-derived cannabinoids.

Holland ML, Lau DT, Allen JD, Arnold JC.

Br J Pharmacol. 2007 Nov;152(5):815-24. Epub 2007 Oct 1.


Differential inhibition of murine Bcrp1/Abcg2 and human BCRP/ABCG2 by the mycotoxin fumitremorgin C.

González-Lobato L, Real R, Prieto JG, Alvarez AI, Merino G.

Eur J Pharmacol. 2010 Oct 10;644(1-3):41-8. doi: 10.1016/j.ejphar.2010.07.016. Epub 2010 Jul 22.


Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance.

Shi Z, Tiwari AK, Shukla S, Robey RW, Singh S, Kim IW, Bates SE, Peng X, Abraham I, Ambudkar SV, Talele TT, Fu LW, Chen ZS.

Cancer Res. 2011 Apr 15;71(8):3029-41. doi: 10.1158/0008-5472.CAN-10-3820. Epub 2011 Mar 14.


Efflux transporter mRNA expression profiles in differentiating JEG-3 human choriocarcinoma cells as a placental transport model.

Ikeda K, Yamasaki K, Homemoto M, Yamaue S, Ogawa M, Nakao E, Fukunaga Y, Nakanishi T, Utoguchi N, Myotoku M, Hirotani Y.

Pharmazie. 2012 Jan;67(1):86-90.


Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.

Dai CL, Tiwari AK, Wu CP, Su XD, Wang SR, Liu DG, Ashby CR Jr, Huang Y, Robey RW, Liang YJ, Chen LM, Shi CJ, Ambudkar SV, Chen ZS, Fu LW.

Cancer Res. 2008 Oct 1;68(19):7905-14. doi: 10.1158/0008-5472.CAN-08-0499. Erratum in: Cancer Res. 2008 Dec 15;68(24):10387.


Identification of compounds that correlate with ABCG2 transporter function in the National Cancer Institute Anticancer Drug Screen.

Deeken JF, Robey RW, Shukla S, Steadman K, Chakraborty AR, Poonkuzhali B, Schuetz EG, Holbeck S, Ambudkar SV, Bates SE.

Mol Pharmacol. 2009 Nov;76(5):946-56. doi: 10.1124/mol.109.056192. Epub 2009 Jul 24.

Supplemental Content

Support Center